Prothena Q3 Loss Widens to 32 Cents a Share, Revenue Collapses 74%
PRTA is trading near its 52-week low of $7.73 (2.1% above the low).
Summary
Prothena posted a Q3 adjusted loss of 32 cents a share, wider than the 21-cent loss six analysts expected and worse than the 68-cent loss a year ago on a per-share basis. Revenue fell 74.3% to $620,000 against a $9.58 million consensus — a big top-line miss. The net loss was $16.51 million, and the company still holds roughly $272 million in cash, so funding is not the immediate issue. The miss lands three weeks after Bristol Myers Squibb terminated the PRX019 license effective January 2027, leaving Prothena with no economics on that program. Shares sit near the 52-week low of $7.73, down 12.1% year to date, even as 10% owner William Scully has been accumulating stock through October.
At the time of this announcement, PRTA was trading at $7.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $405M. The 52-week trading range was $7.73 to $11.80. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.